Prostate Cancer Drug Therapy: What Have Clinicians Missed During the COVID-19 Pandemic.
Mohammad Sajjad RahnamaiPublished in: American journal of men's health (2022)
Due to the COVID-19 pandemic, major congresses and many teaching opportunities as well as the usual visits from medical advisors of pharmaceutical firms have been postponed and canceled. The major trials of prostate cancer in the last 5 years in each state are shortly discussed providing a panoramic overview of the available evidence and data on prostate cancer treatment. Apalutamide, enzalutamide, and darolutamide have proven to have clinical benefits when added to androgen deprivation therapy for patients with nonmetastatic castration-resistant prostate cancer. In patients in the metastatic hormone-sensitive setting, next to docetaxel, abiraterone, enzalutamide, and apalutamide have been shown to significantly improve overall survival and progression-free survival in comparison to standard hormone therapy. In addition, docetaxel abiraterone and enzalutamide are widely used in the metastatic setting. For second-line therapy of metastasized prostate cancer patients who have received either docetaxel or abiraterone or enzalutamide, olaparib, cabazitaxel, radium, and lutetium therapy have been shown to be beneficial in selected patient groups.
Keyphrases
- prostate cancer
- radical prostatectomy
- free survival
- squamous cell carcinoma
- small cell lung cancer
- end stage renal disease
- healthcare
- emergency department
- ejection fraction
- chronic kidney disease
- newly diagnosed
- locally advanced
- palliative care
- mesenchymal stem cells
- electronic health record
- peritoneal dialysis
- benign prostatic hyperplasia
- prognostic factors
- adverse drug
- patient reported